Eurofins Discovery Launches DiscoveryAI SAFIRE Platform to Accelerate Drug Discovery Research
LUXEMBOURG, February 29, 2024
(BUSINESS WIRE) — Regulatory News:
Eurofins Discovery, part of the Eurofins network of laboratories and a leading provider of products and services for drug discovery research, has officially announced the launch of DiscoveryAI SAFIRE (Suite of ADMET Predictions For In Silico Refinement and Evaluation). This advanced platform utilizes proprietary datasets, artificial intelligence (AI), and machine learning (ML) to offer a unique and effective tool for expediting the drug discovery process. SAFIRE is now available for customer use through the Eurofins Discovery website.
The team at Eurofins Discovery has gathered vast and diverse datasets to predict the ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of molecules. This approach sets a new standard in predictive analytics for drug discovery research.
SAFIRE leverages data from Eurofins Discovery’s BioPrint database, which has been curated over years of meticulous research and data accumulation. The result is a powerful research tool that surpasses the limitations of existing predictive systems in the market, as shown in a recent publication in the Future Medical Chemistry journal.
Designed with end-users in mind, SAFIRE offers essential features such as scoring functionality to assist in decision-making and a comprehensive suite of predictive ADME models. The platform has proven to accelerate drug discovery projects from initial hit discovery to lead optimization.
One of the key advantages of SAFIRE is its ability to go beyond the limits of existing predictive systems in the market. Recent results have demonstrated how Eurofins Discovery’s models can predict ADMET properties of molecules quickly and efficiently when trained with proprietary data from the BioPrint database along with public datasets utilized by the SAFIRE platform. This method has shown improved model performance and expanded the chemical space covered by the models, achieving high levels of accuracy and correlation coefficients.
Eurofins Discovery remains committed to keeping SAFIRE dynamic by providing regular updates, expanding its chemical space, and incorporating the latest advancements in AI and ML technologies. For more information on SAFIRE’s benefits and its significant value to the drug discovery community, visit the Eurofins Discovery website.
About Eurofins: The Global Leader in Bio-Analysis
Eurofins is Testing for Life. The Eurofins network of companies is a global leader in food, environment, pharmaceutical, and cosmetic product testing. With a portfolio of over 200,000 analytical methods, Eurofins offers services in areas such as discovery pharmacology, advanced material sciences, and agroscience contract research. The company’s commitment to innovation and quality has positioned it as a market leader in various testing and laboratory services.
With a workforce of approximately 62,000 employees across more than 900 laboratories in 62 countries, Eurofins continues to expand its technology portfolio and geographic reach through R&D and strategic acquisitions. The company’s mission is to provide high-quality services, innovative solutions, and accurate results to meet the evolving demands of clients and regulatory authorities worldwide.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange.
For more information on Eurofins, please visit www.eurofins.com or contact Investor Relations at Eurofins Scientific SE.
Important disclaimer: This press release contains forward-looking statements and estimates. Eurofins Scientific disclaims any intent or obligation to update these forward-looking statements and estimates.
Contacts:
For more information, visit: www.eurofins.com
Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
